Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$10.03
$0.57(5.68%)
At close: 4:00 PM EDT
$10.03
$0.57(5.68%)
Day’s Range― - ―
52-Week Range$2.22 - $14.53
Previous CloseN/A
Volume33.82K
Average Volume (3M)572.32K
Market Cap
$572.01M
Enterprise Value$42.76
Total Cash (Recent Filing)$349.39M
Total Debt (Recent Filing)$9.85M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 18, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding48,890,120
10 Day Avg. Volume428,090
30 Day Avg. Volume572,322
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.90Price Target Upside218.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityRobust Phase 2a outcomes (71% ACR50, deep B-cell depletion, favorable tolerability) materially de-risk AlloNK’s mechanism across B-cell autoimmune indications. Durable clinical proof-of-concept improves probability of successful registrational trial and long-term commercial potential.
Regulatory PositioningRMAT status plus FDA agreement on a single Phase 3 registrational design reduces regulatory uncertainty and can accelerate development timelines. This structural regulatory support enhances the durability of the company’s path to approval and potential label expansion.
Low Leverage And Stronger CapitalizationVery low debt and a step-up in reported equity provide balance-sheet flexibility uncommon for a clinical-stage biotech. Lower refinancing risk and stronger capitalization improve the company’s ability to fund trials and absorb development variability over the next several quarters.
Bears Say
High Cash BurnPersistent, large operating and free cash outflows indicate the business consumes significant cash to advance trials. That structural burn-rate necessitates repeated financing, constrains strategic optionality, and remains a core fundamental risk over a multi-quarter horizon.
No Recent Revenue / Ongoing LossesAbsence of product revenue and sustained multi-year losses mean the company lacks commercial cash generation. Until regulatory approval and commercialization, profitability and margins remain theoretical, forcing continued dependence on capital markets for operations.
Reliance On Equity Financings (dilution Risk)Repeated large equity raises and a new $400M shelf show structural reliance on dilution to fund development. While this supplies capital, it also repeatedly dilutes existing holders and can constrain long-term shareholder alignment and financial leverage options.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $2.22 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $572.01M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 88 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.625 by -$0.005.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 48,890,120 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.625. Following the earnings report the stock price went down -2.677%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.90 (218.00% Upside)
$31.90 (218.00% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 13.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $33.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
186.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
117.62%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$31.90
▲(218.00% Upside)
Technical Analysis
Ownership Overview
55.93% Insiders
1.16% Mutual Funds
4.98% Other Institutional Investors
34.95% Public Companies and
Individual Investors